News Release

August 8, 2018
JCR Pharmaceuticals Co., Ltd.

Translation

**JCR Announces Acquisition of "Kurumin" Certification to Support the Development of the Next Generation**

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that the company has received the "Kurumin" Certification from the Minister of Health, Labour and Welfare (MHLW), in compliance with certification criteria based on Japan's Act on Advancement of Measures to Support Raising Next-Generation Children.

The "Kurumin" certification system formulates and implements action plans for both employees' work and child-rearing, based on the Act on Advancement of Measures to Support Raising Next-Generation Children. Companies whose results meet certain requirements are certified by the MHLW as a "child raising support company."

【Main activities evaluated】

1. Promoting childcare leaves among male employees
2. Improvement of workplace environment, ensuring that every employee is able to easily obtain childcare leave
3. Support for returning to work, including measures for promoting the use of in-house childcare center
4. A review of the working style, such as reducing overtime work




We will continue to proactively engage in reforms of working styles and promote diversity, enabling every employee to display his/her talent and actively and comfortably engage in his/her tasks.

**[About JCR Pharmaceuticals]**

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, "Contributing towards people's healthcare through pharmaceutical products" drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.

***[Cautionary Statement Regarding Forward-Looking Statements]***

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

END

###